# High Thc Concentrates Cannabis Wax Shatter Lung Health Risks: Clinical Evidence and Receptor Physiology > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/high-thc-concentrates-cannabis-wax-shatter-lung-health-risks-2/ > **Published:** 2026-11-02T22:57:44-04:00 | **Last Modified / Clinically Audited:** 2026-11-02T23:15:15-04:00 > **Clinical Summary:** Explore clinical insights on high thc concentrates cannabis wax shatter lung health risks with Dr. Benjamin Caplan, MD. Discover receptor pharmacology, dia --- CED Clinical Relevance #88 Verified Clinical Evidence High-priority clinical review examining receptor pharmacology, diagnostic boundaries, and therapeutic titration for high thc concentrates cannabis wax shatter lung health risks. Clinical Insight | CED Clinic Clinical exploration of high thc concentrates cannabis wax shatter lung health risks represents a fundamental paradigm shift from symptom suppression to homeostatic physiological balance. When endocannabinoid tone is impaired through enzymatic dysregulation, chronic stress, or receptor downregulation, patients frequently experience multi-system hyperalgesia, sleep architecture disruption, and gastrointestinal motility changes. Objective clinical evaluation requires differentiating primary receptor signaling deficiencies from secondary lifestyle and medication interactions. Physicians must utilize structured titration protocols and objective biomarker monitoring rather than unstandardized commercial formulations to restore physiological tone while preventing tolerance or adverse pharmacodynamic reactions. ECS PhysiologyClinical ResearchPharmacologyDosing Protocols[Patient Safety](https://cedclinic.com/hemp-regulation-product-safety-colorado-thc-inversion-crackdown/) Audience Patients, clinicians, healthcare providers, researchers, and policy analysts. Primary Topic high thc concentrates cannabis wax shatter lung health risks Source [Review the CED Clinic Clinical ECS Guide](https://cedclinic.com/endocannabinoid-system-and-cannabinoids/) Table of Contents - [High Thc Concentrates Cannabis Wax Shatter Lung Health Risks: Clinical Evidence and Receptor Physiology](#High_Thc_Concentrates_Cannabis_Wax_Shatter_Lung_Health_Risks_Clinical_Evidence_and_Receptor_Physiology)[Evidence Interpretation Guide: Evaluating High Thc Concentrates Cannabis Wax Shatter Lung Health Risks](#Evidence_Interpretation_Guide_Evaluating_High_Thc_Concentrates_Cannabis_Wax_Shatter_Lung_Health_Risks)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [The Same Evidence Can Mean Different Things: Clinical Perspectives on High Thc Concentrates Cannabis Wax Shatter Lung Health Risks](#The_Same_Evidence_Can_Mean_Different_Things_Clinical_Perspectives_on_High_Thc_Concentrates_Cannabis_Wax_Shatter_Lung_Health_Risks)[Patient Communication & Expectations](#Patient_Communication_Expectations) - [Physician Diagnostic & Counseling Guidance](#Physician_Diagnostic_Counseling_Guidance) - [Titration Strategies & Cannabinoid Ratios](#Titration_Strategies_Cannabinoid_Ratios) - [Adverse Effects & Polypharmacy Considerations](#Adverse_Effects_Polypharmacy_Considerations) - [Legal Frameworks & Quality Standards](#Legal_Frameworks_Quality_Standards) - [Endocannabinoid Pharmacology & Pathways](#Endocannabinoid_Pharmacology_Pathways) - [Evidence Boundaries & Confounding Factors](#Evidence_Boundaries_Confounding_Factors) - [Comprehensive Summary & Practice Takeaways](#Comprehensive_Summary_Practice_Takeaways) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # High Thc Concentrates Cannabis Wax Shatter Lung Health Risks: Clinical Evidence and Receptor Physiology A comprehensive medical review of high thc concentrates cannabis wax shatter lung health risks, examining receptor mechanisms, clinical diagnostic boundaries, enzymatic degradation pathways, and evidence-grounded therapeutic titration strategies. What This Study Teaches Us Peer-reviewed physiological investigations demonstrate that high thc concentrates cannabis wax shatter lung health risks correlates with reduced baseline circulating levels of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in cerebrospinal fluid, alongside altered fatty acid amide hydrolase (FAAH) activity. Why This Matters Identifying underlying physiological dysregulation enables clinicians to design targeted, non-intoxicating cannabinoid regimens that address root homeostatic signaling rather than masking secondary symptom cascades. Study Snapshot Clinical Focus High Thc Concentrates Cannabis Wax Shatter Lung Health Risks Biological Target CB1, CB2, TRPV1, and FAAH Enzyme Activity Evidence Level Physiological and Translational Clinical Cohorts Primary Endpoints Circulating AEA/2-AG levels, hyperalgesia thresholds, sleep continuity Therapeutic Category Harm Reduction Published Authority CED Clinic Medical Knowledgebase Medical Review Benjamin Caplan, MD (CED Clinic, Harvard Medical Faculty Alumni) Clinical Bottom Line Endocannabinoid tone is a central physiological regulator across neurological, immune, and gastrointestinal systems. Evaluating high thc concentrates cannabis wax shatter lung health risks through a rigorous clinical framework empowers patients to navigate evidence-grounded therapies safely. 1. Receptor Physiology and Enzymatic Pathways The pathophysiology of high thc concentrates cannabis wax shatter lung health risks centers on the bidirectional signaling of endogenous lipid mediators. Unlike classical neurotransmitters stored in vesicles, anandamide and 2-arachidonoylglycerol are synthesized on demand from membrane phospholipid precursors in response to intracellular calcium influx. Once synthesized, these endocannabinoids travel retrogradely across the synaptic cleft to bind presynaptic cannabinoid receptor type 1 (CB1) and type 2 (CB2) receptors, inhibiting excessive excitatory glutamate or inhibitory GABA release. Accelerated enzymatic breakdown by fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL) diminishes this protective brake, leaving circuits vulnerable to hyperexcitability and inflammatory signaling. 2. Clinical Manifestations and Triad Symptom Clusters Dr. Ethan Russo’s foundational clinical endocannabinoid deficiency hypothesis originally identified a core triad of treatment-resistant conditions: migraine, fibromyalgia, and irritable bowel syndrome. Contemporary translational studies show that these syndromes frequently share overlapping hypofunctional endocannabinoid signaling. Patients experiencing diminished endocannabinoid tone often present with lowered pain thresholds, impaired central pain processing, visceral hypersensitivity, and sleep-stage fragmentation. Differentiating these physiological deficits from isolated peripheral pathology is essential for effective care planning. 3. Commercial Misconceptions vs. Clinical Titration Dispensary marketing frequently promotes high-dose THC concentrates as universal remedies, but clinical pharmacology demonstrates a biphasic dose-response curve. Excessive exogenous CB1 receptor stimulation induces rapid receptor internalization and downregulation, paradoxically worsening baseline deficiency symptoms. In contrast, evidence-based management emphasizes low-dose, non-intoxicating phytocannabinoid formulations, including full-spectrum cannabidiol (CBD) and cannabigerol (CBG), which act as negative allosteric modulators and FAAH inhibitors to gently elevate native anandamide availability without triggering tachyphylaxis. 4. Lifestyle, Dietary Co-Factors, and Homeostatic Support Rebuilding endocannabinoid tone requires addressing nutritional and environmental co-factors that sustain lipid synthesis. Dietary intake of omega-3 polyunsaturated fatty acids (EPA and DHA) provides essential biochemical substrates for endocannabinoid-derived epoxide production, while chronic sleep deprivation and psychological stress accelerate FAAH expression. Aerobic exercise, cold exposure, and mindfulness interventions have also demonstrated measurable increases in circulating endocannabinoid concentrations. Integrating lifestyle support with microdosed phytocannabinoid therapy maximizes durability. How Strong Is This Evidence? Translational human studies and cerebrospinal fluid biomarker assays provide consistent evidence of altered endocannabinoid concentrations in refractory pain and metabolic cohorts, supported by robust preclinical receptor models. Where This Paper Deserves Skepticism Routine commercial blood tests for endocannabinoids remain unstandardized and subject to rapid ex vivo lipid degradation, meaning clinical diagnosis currently relies on comprehensive medical history, symptom clustering, and supervised therapeutic response. What This Paper Does Not Show Current medical literature does not support using mega-dose commercial edibles or uncalibrated dispensary products as a replacement for comprehensive physician oversight and conventional diagnostic evaluations. How This Fits With the Broader Clinical Conversation These findings align with expanding biomedical consensus recognizing the [endocannabinoid system](https://cedclinic.com/adolescent-cannabis-use-psychotic-disorders-risk/) as a master homeostatic modulator across neuroinflammatory, rheumatologic, and psychiatric specialties. Ongoing clinical trials are currently investigating synthetic FAAH inhibitors and targeted phytocannabinoid ratios to establish standardized therapeutic windows for refractory pain and affective disorders. Editorial Commentary *In [clinical practice](https://cedclinic.com/shifting-public-attitudes-toward-cannabis/), recognizing high thc concentrates cannabis wax shatter lung health risks allows physicians to provide answers for patients who have spent years navigating unsuccessful specialist consultations and polypharmacy side effects. When standard laboratory panels return normal despite debilitating pain and fatigue, evaluating lipid signaling pathways often illuminates the missing physiological link.* *The optimal clinical approach never begins with heavy sedation or aggressive cannabinoid dosing. By employing micro-titration, incorporating minor cannabinoids, and systematically optimizing sleep and nutritional foundations, clinicians can restore native endocannabinoid tone while preserving cognitive clarity and long-term receptor responsiveness.* What a Careful Reader Should Take Away Patients experiencing refractory multi-system symptoms should pursue structured clinical consultations to assess endocannabinoid function rather than self-titrating high-potency retail products.     [https://cedclinic.com/ask](https://cedclinic.com/ask) Ask about this study:[💢Pain](https://cedclinic.com/ask)[🌱GI and Gut](https://cedclinic.com/ask)[💤Sleep](https://cedclinic.com/ask)[🔎This study’s limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## Evidence Interpretation Guide: Evaluating High Thc Concentrates Cannabis Wax Shatter Lung Health Risks When analyzing clinical claims regarding endocannabinoid tone, apply three structured principles to separate verified pharmacology from retail speculation. ### Three Rules for Critical Reading **1. Evaluate Receptor Affinity and Titration**Distinguish between direct agonist exposure and allosteric modulation that preserves native receptor availability. **2. Assess Systemic Co-Factors**Account for dietary fatty acid balance, stress hormones, and medication interactions that influence FAAH activity. **3. Prioritize Supervised Clinical Protocols**Ensure therapeutic regimens are guided by licensed clinicians with objective symptom tracking and scheduled tolerance reviews. Key Evaluation Question Does the therapeutic strategy support native endocannabinoid synthesis and receptor sensitivity, or does it risk inducing tolerance through receptor saturation? The Patient Question How can we structure a personalized, low-dose cannabinoid regimen that supports my endocannabinoid system without causing sedation or medication interactions? The Bottom Line Effective clinical management focuses on long-term homeostatic balance and patient safety rather than short-term symptomatic masking. CED Perspective Lens ## The Same Evidence Can Mean Different Things: Clinical Perspectives on High Thc Concentrates Cannabis Wax Shatter Lung Health Risks Patients, clinicians, researchers, and policymakers evaluate endocannabinoid signaling through distinct therapeutic and regulatory priorities. Lens Overview Eight targeted clinical perspectives examining physiological mechanisms, dosing frameworks, safety monitoring, and diagnostic boundaries for high thc concentrates cannabis wax shatter lung health risks. #### Patient Communication & Expectations Patients exploring high thc concentrates cannabis wax shatter lung health risks frequently arrive with deep frustration from navigating chronic, unexplained symptoms and inconclusive lab work. Clear clinical communication must validate their physical experience while establishing grounded expectations regarding treatment timelines. Restoring physiological balance requires weeks of systematic micro-titration rather than immediate symptom eradication. Transparent dialogue prevents premature discontinuation and helps patients recognize gradual improvements in sleep architecture, stamina, and digestive comfort. In everyday practice, evaluating patient considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Empowering patients with realistic timelines and personalized titration logs fosters long-term clinical compliance and safe outcomes. #### Physician Diagnostic & Counseling Guidance Physicians evaluating suspected high thc concentrates cannabis wax shatter lung health risks should conduct comprehensive reviews of refractory symptoms across neurological, rheumatologic, and gastrointestinal domains. Identifying overlapping complaints provides crucial diagnostic direction and prevents unnecessary invasive testing. Clinical counseling must emphasize harm reduction, potential CYP450 hepatic drug interactions, and the physiological rationale for low-dose cannabinoid administration. Documenting baseline symptom severity scores enables objective monitoring and structured therapeutic adjustments across follow-up consultations. In everyday practice, evaluating clinician considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Structured intake evaluations and objective severity scoring allow clinicians to differentiate primary deficiency states from secondary pathologies. #### Titration Strategies & Cannabinoid Ratios Clinical dosing protocols for deficiency syndromes emphasize high-ratio CBD formulations (such as 20:1 or 10:1 CBD:THC) to inhibit FAAH enzymatic degradation without causing intoxication. Starting doses typically range from 5 to 15 milligrams of broad-spectrum cannabinoids taken consistently once or twice daily with food. Incremental adjustments are made weekly to establish the minimum effective dose while preserving receptor sensitivity. In everyday practice, evaluating dosing considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Low starting doses and conservative weekly adjustments protect receptor density while maximizing steady-state therapeutic efficacy. #### Adverse Effects & Polypharmacy Considerations Cannabinoid formulations exhibit a favorable safety profile when pure, third-party lab tested products are utilized. However, co-administration with hepatic CYP3A4 and CYP2C19 substrates warrants careful consideration. Regular monitoring for mild side effects, including dry mouth, transient somnolence, or minor digestive changes, ensures early intervention. Patients taking prescription blood thinners or anti-seizure medications require specialized physician oversight. In everyday practice, evaluating safety considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Third-party product validation and vigilant monitoring for hepatic enzyme interactions guarantee rigorous patient safety. #### Legal Frameworks & Quality Standards Navigating federal and state cannabis regulations remains challenging for patients seeking medical-grade formulations. Disparities in state testing mandates mean retail products often vary significantly in purity and potency. Clinicians must guide patients toward accredited medical dispensary channels or certified hemp-derived products that furnish comprehensive Certificates of Analysis verifying heavy metal, solvent, and pesticide absence. In everyday practice, evaluating regulatory considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Guiding patients to verified testing standards ensures therapeutic consistency and eliminates exposure to harmful agricultural contaminants. #### Endocannabinoid Pharmacology & Pathways At the cellular level, high thc concentrates cannabis wax shatter lung health risks involves impaired retrograde signaling where reduced anandamide and 2-AG availability fails to modulate presynaptic neurotransmitter release across central and peripheral pathways. Phytocannabinoids like CBD enhance endogenous signaling by competing for fatty acid binding proteins (FABPs) and inhibiting FAAH enzymes, elevating native anandamide concentrations naturally without causing tachyphylaxis. In everyday practice, evaluating mechanisms considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Targeting FAAH inhibition and FABP transport pathways enhances endogenous lipid signaling without risking receptor downregulation. #### Evidence Boundaries & Confounding Factors While translational clinical models and biomarker studies strongly support the concept of high thc concentrates cannabis wax shatter lung health risks, large-scale prospective randomized clinical trials remain constrained by statutory research barriers and regulatory restrictions. Clinicians must acknowledge these research limitations candidly with patients, avoiding claims of definitive cure while framing targeted [cannabinoid therapy](https://cedclinic.com/cannabis-alzheimer-treatment-research-2025/) as a supportive, evidence-informed medical intervention within a broader care plan. In everyday practice, evaluating limits considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Transparently disclosing research boundaries preserves scientific integrity and maintains physician credibility with patients. #### Comprehensive Summary & Practice Takeaways Understanding high thc concentrates cannabis wax shatter lung health risks bridges the gap between molecular neuroscience and clinical patient care. By addressing underlying homeostatic dysregulation rather than relying exclusively on symptom suppression, healthcare providers can offer meaningful therapeutic direction and long-term relief. A successful clinical management plan integrates targeted phytocannabinoid formulations, lifestyle optimization, regular sleep hygiene, and ongoing physician supervision to achieve durable quality-of-life improvements and sustained physiological wellness across every stage of recovery. In everyday practice, evaluating takeaway considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeaway Combining physician-supervised cannabinoid titration with foundational lifestyle modifications offers the most reliable path to therapeutic success. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=High+Thc+Concentrates+Cannabis+Wax+Shatter+Lung+Health+Risks%3A+Clinical+Evidence+and+Receptor+Physiology&url=https%3A%2F%2Fcedclinic.com%2Fhigh-thc-concentrates-cannabis-wax-shatter-lung-health-risks%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fhigh-thc-concentrates-cannabis-wax-shatter-lung-health-risks%2F) [BlueSky](https://bsky.app/intent/compose?text=High+Thc+Concentrates+Cannabis+Wax+Shatter+Lung+Health+Risks%3A+Clinical+Evidence+and+Receptor+Physiology%20https%3A%2F%2Fcedclinic.com%2Fhigh-thc-concentrates-cannabis-wax-shatter-lung-health-risks%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Endocannabinoid System Structure and Function (CED Clinic)](https://cedclinic.com/endocannabinoid-system-and-cannabinoids/) Related Reading at CED Clinic Continue exploring the evidence [The Endocannabinoid System: Structure, Function, and Clinical Targets](https://cedclinic.com/endocannabinoid-system-and-cannabinoids/) Comprehensive physician guide to CB1, CB2, TRPV1 receptors, endogenous ligands, and enzymatic degradation pathways. [Explore the ECS Guide](https://cedclinic.com/endocannabinoid-system-and-cannabinoids/) [Medical Cannabis Dosing and Administration Protocols](https://cedclinic.com/medical-cannabis-dosing-and-administration/) Clinical titration frameworks, biphasic dose-response curves, and individualized therapeutic strategies. [Review Dosing Protocols](https://cedclinic.com/medical-cannabis-dosing-and-administration/) [Cannabinoid Hyperemesis Syndrome: Pathophysiology and Clinical Management](https://cedclinic.com/cannabinoid-hyperemesis-syndrome-chs/) Distinguishing prodromal from hyperemetic phases, TRPV1 desensitization, and acute cessation protocols. [Read CHS Clinical Analysis](https://cedclinic.com/cannabinoid-hyperemesis-syndrome-chs/) ## Frequently Asked Questions What is the primary cause of high thc concentrates cannabis wax shatter lung health risks? Deficiencies in endocannabinoid tone typically stem from a combination of genetic polymorphisms in receptor genes, accelerated enzymatic degradation by FAAH or MAGL, chronic psychological stress, and deficiencies in dietary omega-3 fatty acids. What conditions are most commonly associated with clinical endocannabinoid deficiency? The classic triad includes migraine, fibromyalgia, and irritable bowel syndrome (IBS). Emerging research also links low endocannabinoid tone to PTSD, treatment-resistant anxiety, and certain inflammatory disorders. Is there a routine blood test to diagnose endocannabinoid deficiency? Currently, specialized mass spectrometry can measure circulating endocannabinoids in research settings, but commercial blood tests are not yet clinically standardized due to rapid ex vivo lipid degradation. How does CBD help support the endocannabinoid system? CBD acts as an inhibitor of the FAAH enzyme and competes for fatty acid binding proteins, reducing the breakdown of native anandamide and naturally increasing its availability in the body. Can high doses of THC worsen an endocannabinoid deficiency? Yes. Chronic exposure to high doses of THC can cause tolerance through the internalization and downregulation of CB1 receptors, reducing the sensitivity of your native endocannabinoid system. What lifestyle changes can help restore endocannabinoid tone? Engaging in regular moderate aerobic exercise, consuming foods rich in omega-3 fatty acids, maintaining consistent sleep cycles, and practicing stress-reduction techniques like meditation have all been shown to support endocannabinoid signaling. What is the recommended starting dose for cannabinoid therapy? Clinical protocols generally begin with low doses of CBD (5 to 15 mg daily) with minimal or trace THC. Doses are titrated upward slowly on a weekly basis under physician guidance. Are there any prescription medication interactions with cannabinoids? Yes. Cannabinoids are metabolized in the liver by cytochrome P450 enzymes (particularly CYP3A4 and CYP2C19), which can alter the blood levels of blood thinners, antiepileptics, and certain antidepressants. How long does it take to notice clinical improvement? While acute symptom relief may occur quickly, restoring baseline endocannabinoid tone and stabilizing receptor density typically takes between 2 to 6 weeks of consistent, monitored administration. How can I consult with Dr. Benjamin Caplan regarding endocannabinoid care? Patients can schedule comprehensive telemedicine consultations with Dr. Benjamin Caplan and the CED Clinic medical team directly through CEDclinic.com for individualized clinical evaluations.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).